Shipping Pharmaceuticals Safely

Pharmaceutical logistics operates under a stricter set of requirements than almost any other freight category. The products involved — prescription drugs, biologics, vaccines, and controlled substances — are temperature-sensitive, heavily regulated, and high-value targets for theft. A single lapse in temperature control, documentation, or chain of custody can render an entire shipment unsalvageable or trigger regulatory consequences for everyone involved.

This article covers what shippers, carriers, and logistics partners need to understand about moving pharmaceutical freight safely and compliantly: the regulatory framework that governs it, the cold chain requirements that protect product integrity, the documentation standards that create accountability, the security protocols that reduce theft exposure, and what to look for in a 3PL with genuine pharmaceutical experience.

Rules and Regulations for Shipping Pharmaceuticals

Pharmaceutical shipping in the United States doesn’t answer to a single regulator — it sits at the intersection of several overlapping federal frameworks, each with distinct requirements and its own enforcement arm. Knowing what each one covers, and who’s on the hook for what, is essential before any pharmaceutical load moves.

FDA Current Good Manufacturing Practice (cGMP): CFR Title 21, Parts 210 and 211

The FDA’s cGMP regulations set the baseline for manufacturing, processing, packaging, and holding pharmaceutical products. For logistics, the most relevant requirements come down to three things: maintaining temperature control throughout storage and transit, keeping vehicles and facilities clean enough to prevent contamination, and documenting every handling step. The full text lives in the Code of Federal Regulations Title 21. It’s dense, but it governs every entity that touches finished pharmaceutical products in the supply chain.

Good Distribution Practice (GDP)

GDP guidelines sit within CFR Title 21 and align with standards set by the World Health Organization and the European Medicines Agency. Where cGMP covers manufacturing broadly, GDP zeroes in on the distribution phase specifically: temperature mapping and monitoring, equipment calibration, personnel training, risk assessment, and written procedures for handling excursions. For carriers and 3PLs, GDP compliance isn’t a differentiator. It’s the baseline entry requirement for handling pharmaceutical freight.

Drug Supply Chain Security Act (DSCSA)

Passed in 2013, the DSCSA created a federal framework for tracking and tracing prescription drugs at the package level as they move through the supply chain. Its final serialization phase (electronic, unit-level traceability) is now in effect, with staggered deadlines that ran through 2025 for manufacturers and wholesale distributors and extend to 2026 for some smaller dispensers.

Every trading partner covered by DSCSA, including manufacturers, wholesale distributors, repackagers, dispensers, and 3PLs, must exchange transaction documentation electronically every time ownership changes hands. Records have to be kept for at least six years. The penalties for non-compliance are serious: civil fines up to $500,000 per violation, with criminal charges possible for intentional violations.

Who Bears Responsibility

Regulatory responsibility doesn’t sit with one party; it’s distributed across the chain. Manufacturers own labeling and serialization. Carriers and 3PLs own conditions in transit and documentation on request. Distributors and dispensers own credential verification and chain-of-custody records. A gap anywhere creates exposure everywhere downstream, which is why pharmaceutical logistics runs on active coordination, not assumed handoffs.

Four Core Requirements for Pharmaceutical Shipping

Whatever the product, pharmaceutical freight handling comes back to four fundamentals. These aren’t best practices or nice-to-haves — they’re the floor.

Temperature Control

Temperature is where pharmaceutical logistics gets most demanding, and where product loss is most likely when something goes wrong. Different products require different ranges, and hitting those ranges consistently from the manufacturer’s loading dock to the final delivery point isn’t optional.

There are four primary classifications:

• Refrigerated (2–8°C): The most common, covering most vaccines, biologics, insulin, and injectable medications. These products are sensitive to both warming and freezing. A brief excursion in either direction can permanently compromise efficacy.
• Controlled room temperature (15–25°C): Required for many oral medications, certain topicals, and some OTC pharmaceuticals. Less demanding than cold chain, but validated equipment and monitoring are still required.
• Frozen (-20°C): Certain biologics, plasma products, and specialty medications fall here. Validated frozen packaging or vehicles capable of maintaining sub-zero conditions throughout transit are non-negotiable.
• Cryogenic (-70°C and below): mRNA vaccines, gene therapies, CAR-T cell treatments. These require specialized dry ice or liquid nitrogen packaging and carriers with specific training and handling capabilities.

Industry estimates put temperature excursions at roughly 30% of pharmaceutical shipments. Every excursion has to be documented, investigated, and assessed before the affected product can be released or disposed of, which makes continuous, calibrated monitoring throughout transit a requirement, not an upgrade.

Cleanliness

Pharmaceutical products can be compromised by residue, moisture, pests, and cross-contact with other cargo. FDA cGMP requires vehicles and facilities to be kept clean and inspected regularly. Dedicated vehicles (those used exclusively for pharmaceutical or food-grade freight) are the preferred standard. When that’s not possible, documented cleaning and inspection between loads is required to confirm the vehicle was fit before loading.

Protection

Pharmaceutical freight needs physical protection at every stage: packaging that holds up under expected transit conditions, loading and unloading procedures that limit unauthorized access, and continuous custody monitoring from origin to destination. For controlled substances and high-value biologics, that extends to GPS tracking, sealed and locked trailers, and documented chain-of-custody at every handoff.

Documentation

In pharmaceutical logistics, documentation isn’t a formality — it’s how compliance gets proven and product integrity gets verified. Required records include temperature logs for the full transit duration, vehicle inspection and cleaning records, chain-of-custody documentation at every ownership transfer, and DSCSA transaction information. Under 21 CFR 205.50, prescription drug distributors are required to maintain storage and handling records and produce them for regulators on request. DSCSA records must be retained for six years minimum and available electronically when requested.

Maintaining Cold Chain Integrity from Start to Finish

Cold chain integrity means keeping a product’s required temperature range unbroken from the manufacturer to the end destination. When the chain holds, the product arrives with its potency, stability, and safety profile intact. When it breaks, even briefly, the damage may be permanent and the product may not be recoverable.

Where Cold Chains Break

Most temperature excursions don’t happen mid-route. They happen at handoff points: loading and unloading, vehicle transfers, warehouse staging areas, and final-mile delivery. A refrigerated truck that maintains 4°C for 12 hours can still deliver a compromised product if the receiving dock isn’t temperature-controlled or if the shipment sits on a staging dock longer than it should.

Other common failure points include equipment malfunctions with no real-time alerting, packaging that wasn’t validated for the actual transit profile, vehicles or packaging that weren’t pre-conditioned before loading, and handling by personnel who haven’t been trained on the specific product requirements.

Monitoring Requirements

Continuous, calibrated temperature monitoring throughout transit is a GDP requirement — not an optional enhancement. Monitoring systems need to be validated for the product’s specific temperature range, log data at regular intervals, and generate alerts when temperatures approach or exceed thresholds. Those records become part of the shipment file and have to be available for review if a dispute or regulatory inquiry comes up.

Most modern cold chain monitoring now uses IoT-enabled sensors that transmit temperature and humidity data in real time, which means carriers and shippers can catch and respond to excursions before they become unrecoverable. When evaluating logistics partners, continuous monitoring data and a complete temperature record per shipment should be table stakes — not a selling point.

Excursion Response Protocols

When an excursion happens, how the response is handled matters as much as the excursion itself. GDP requires immediate documentation, a root-cause investigation, and assessment by a qualified person to determine whether the product can be released, quarantined, or has to be destroyed. An excursion that’s properly documented and investigated is a compliance event. One that goes undetected or unrecorded is a serious regulatory failure.

Written excursion response procedures should be in place before a shipment moves — not drafted after something goes wrong. Those procedures need to spell out who gets notified, what gets recorded, how quickly an assessment needs to happen, and what the options are for affected product. A logistics partner with real pharmaceutical experience will have these protocols documented and ready to share.

Warehousing and Storage

Cold chain integrity doesn’t stop at the truck. Warehouses and distribution centers handling pharmaceutical products have to maintain validated temperature and humidity conditions throughout their storage areas, with calibration records for all monitoring equipment. Contingency plans for equipment failures and power outages are also required, not just good practice. For shippers using third-party warehousing as part of a pharmaceutical distribution network, confirming that a facility meets GDP standards and holds appropriate certifications is basic due diligence, worth doing before a product ever enters the building. For a broader overview of how temperature-controlled logistics works across product categories, see our dedicated article.

Documentation Requirements for Pharmaceutical Shipments

Documentation in pharmaceutical logistics does two things at once: it proves regulatory compliance, and it creates the chain of evidence needed to investigate anything that goes wrong in transit. Neither function works if the records aren’t accurate, complete, and kept for the required period.

Transaction Documentation Under DSCSA

Every time a pharmaceutical product changes hands, DSCSA requires all trading partners to exchange three categories of transaction documentation:

• Transaction Information (TI): Product name, strength, dosage form, NDC number, container size, number of containers, lot number, transaction date, shipment date, and the name and address of both the transferor and transferee.
• Transaction History (TH): The complete prior transaction information for the product, going back to the manufacturer.
• Transaction Statement (TS): A statement from the transferor confirming the product isn’t counterfeit, stolen, or otherwise compromised, and that the transferor is licensed or authorized under DSCSA.

All of it has to be exchanged electronically in an interoperable format and kept for at least six years. The FDA or any authorized trading partner can request these records, and they need to be producible promptly. Failure to maintain or produce required documentation is a citable DSCSA violation.

Temperature and Condition Records

Every pharmaceutical shipment needs a complete temperature log covering the full transit, from the moment the product leaves its origin environment to delivery at its destination. That log should include the monitoring device ID and calibration status, timestamped data points throughout transit, any alerts generated, and the actions taken in response.

If a shipment experiences a temperature excursion, the log becomes the primary document in the investigation. It should be kept as part of the shipment record whether the product was released or destroyed.

Vehicle and Facility Inspection Records

FDA cGMP requires that vehicles and storage facilities used for pharmaceutical freight be inspected before use and kept in a condition that prevents contamination. Inspection records should cover the date and scope of each inspection, the condition of the vehicle or facility at that time, any corrective actions taken, and who conducted it. For dedicated pharmaceutical carriers, these records are part of the quality management documentation that gets reviewed during audits and regulatory inspections.

Chain of Custody Documentation

Every handoff in a pharmaceutical shipment, from manufacturer to carrier, carrier to warehouse, warehouse to final-mile carrier, and carrier to recipient, needs a signed record confirming the product’s condition at the time of transfer. Chain of custody documentation creates accountability at each transition point and is essential for tracing the source of any quality or compliance issue that surfaces after delivery.

For controlled substances, chain of custody requirements are enforced by the Drug Enforcement Administration (DEA) on top of FDA and DSCSA requirements. Carriers handling Schedule II through V controlled substances need a current DEA registration and must comply with additional security and recordkeeping requirements specific to controlled substance handling.

Personnel Training Records

GDP requires that everyone involved in pharmaceutical logistics, including drivers, warehouse staff, dock workers, and quality personnel, receive documented training appropriate to their role. Training records should cover what was taught, when it was completed, who delivered it, and when refresher training is due. For carriers and 3PLs trying to demonstrate pharmaceutical logistics competence, current training records are one of the clearest signals that operations are actually built for this kind of freight.

Shielding Pharmaceutical Shipments from Theft

Pharmaceutical cargo is among the most targeted freight categories in the supply chain. Pharmaceuticals account for a small share of total cargo theft incidents overall, but the median value of a pharmaceutical theft runs around $100,000, significantly higher than most other categories, and individual incidents can reach into the millions. In the U.S., opioids, high-value biologics, and specialty medications are the most commonly targeted products, and organized theft networks actively monitor pharmaceutical shipment patterns and facility vulnerabilities.

Effective pharmaceutical security is layered: it covers the vehicle, the facility, the route, and the people involved at every stage.

Vehicle Security

Trailers carrying pharmaceutical freight should have hard-sided construction, high-security locks, and GPS tracking that transmits location in real time. Any unplanned route deviation or unscheduled stop should trigger an immediate alert to a designated security contact. For high-value or controlled substance shipments, dual-driver teams eliminate the stops that create the most theft exposure. Trailer seals should be numbered, recorded at loading, and checked at every subsequent handoff.

Facility Security

Loading docks and warehouses handling pharmaceutical freight are frequent targets, both for opportunistic theft and coordinated break-ins. Access to pharmaceutical storage areas should be restricted to credentialed personnel, with documented access logs for every entry and exit. Dock doors stay closed and monitored when they’re not actively in use, and unattended trailers get secured to a dock door or kingpin-locked when parked on facility grounds. Camera coverage of all dock areas, staging zones, and parking is a baseline requirement for any facility handling high-value pharmaceutical cargo. For a broader look at cargo security, see How to Protect Your Supply Chain From Cargo Theft.

Driver and Personnel Verification

Driver identity should be verified at pickup and delivery. A valid CDL is the minimum, and for controlled substance shipments, a current DEA-authorized carrier credential is also required. Physical descriptions and vehicle information, including tractor and trailer plate numbers, should go to receiving facilities before the shipment arrives. Drivers shouldn’t discuss contents, routes, or schedules with anyone outside the operation. That includes truck stops, rest areas, and fuel stations along the route.

Background screening for anyone with access to pharmaceutical freight, including warehouse staff, dock workers, and contract drivers, is standard in this space. For a look at the licensing and endorsement requirements that apply to drivers handling regulated freight, see The Shipper’s Guide to Licenses and Endorsements.

Route Planning and Stop Minimization

Every stop is a potential theft exposure point. Routes should be planned to minimize them, avoid known high-theft corridors where possible, and use secured, monitored truck stops over unmonitored roadside pullouts. For temperature-sensitive shipments, stop minimization serves double duty: extended stops in uncontrolled environments create both security risk and cold chain risk at the same time.

Pre-planned routes should go only to personnel who need them and should never be shared over unsecured channels. Any significant deviation from a planned route should be reported immediately and documented in the shipment record.

Incident Response

Carriers and 3PLs should have a documented incident response protocol covering what happens in the event of theft, attempted theft, or suspected diversion. For controlled substances, any theft or significant loss must be reported to the DEA within one business day using DEA Form 106. For other pharmaceutical products, report to the shipper immediately and document everything. Prompt, documented incident response is a regulatory requirement for controlled substances and a standard contractual expectation in pharmaceutical logistics more broadly.

What to Look for in a Pharmaceutical Logistics Partner

Not every carrier or 3PL is set up to handle pharmaceutical freight. The requirements covered in this article, including temperature control, documentation, security protocols, and regulatory compliance, call for specific infrastructure, training, and operational processes that go well beyond standard freight capabilities. Selecting a partner without verifying these things is a compliance risk for the shipper. The FDA doesn’t distinguish between who dropped the ball, only that it was dropped.

Here’s a practical framework for evaluating whether a carrier or 3PL can actually handle pharmaceutical freight.

Verified temperature control capabilities. Ask to see validation documentation and calibration records for monitoring equipment. Validation means the equipment has been tested under real-world conditions and shown to maintain the required range throughout the expected transit profile. A partner who can’t produce these records isn’t operating to GDP standards.

Documented quality management system. GDP requires carriers and 3PLs to maintain a documented QMS covering SOPs for temperature control, contamination prevention, personnel training, excursion response, and documentation retention. A dedicated quality or compliance function, rather than treating quality as an informal responsibility, is a strong signal that operations are actually built for this.

DSCSA compliance infrastructure. Any 3PL operating as a DSCSA trading partner needs a current state license and must report that licensure to the FDA annually. They also need the technical infrastructure to exchange transaction information electronically in an interoperable format. Confirm FDA registration, current state licensure in all operating states, and the ability to exchange DSCSA documentation as required.

Controlled substance handling authorization. Transporting Schedule II through V controlled substances requires a current DEA registration, which is separate from standard pharmaceutical carrier credentials. Verify DEA registration before engaging any partner for this type of freight, and confirm the registration covers the specific substance schedules involved.

Security infrastructure and protocols. Ask for specifics, not assurances. A capable partner should be able to describe documented protocols covering vehicle security, facility access controls, personnel verification, route planning, and incident response. GPS tracking with real-time monitoring, hard-sided trailer requirements, and dual-driver policies should be standard for high-value or controlled substance shipments.

Pharmaceutical-specific experience. Regulatory knowledge develops through experience, not certification alone. A partner with a real track record in pharmaceutical freight has handled excursions, navigated DSCSA requirements, managed controlled substance documentation, and operated within the audit environment that pharmaceutical shippers regularly conduct. Ask for references from current pharmaceutical clients, and look for willingness to participate in shipper-conducted audits.

First Call Logistics works with shippers moving temperature-sensitive, high-value, and regulated freight across the country. For questions about pharmaceutical logistics capabilities or to discuss a specific shipment requirement, contact our team.

Getting Pharmaceutical Freight Right

Pharmaceutical logistics is demanding not because the operational basics are different, but because the consequences of getting them wrong extend beyond financial loss to patient safety and regulatory liability. Temperature excursions, documentation gaps, and chain-of-custody failures aren’t just service failures in this context — they’re compliance events with real consequences for every party involved.

The regulatory framework here keeps moving. DSCSA serialization is now in effect across most of the supply chain, cold chain monitoring technology is advancing quickly, and FDA enforcement of GDP standards has increased. Shippers who understand the requirements and work with partners who actually meet them are better positioned to move pharmaceutical freight without incident — and without the kind of regulatory scrutiny that follows when something goes wrong.

For shippers moving refrigerated LTL shipments or temperature-controlled freight more broadly, those articles cover the operational considerations for cold chain logistics in more detail. For freight that requires hazmat handling alongside pharmaceutical compliance requirements, that article covers the regulatory overlap worth understanding before a shipment moves.

Frequently Asked Questions